FindTrial
Sign In

Assessment of efficacy and adverse reactions of ticagrelor by plasma drug concentration and related gene mutations.

Assessment of efficacy and adverse reactions of ticagrelor by plasma drug concentration and related gene mutations.

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023176
Enrollment
Unknown
Registered
2019-05-15
Start date
2019-05-18
Completion date
Unknown
Last updated
2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome

Interventions

case series:Ticagrelor

Sponsors

The First Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: Patients with one of the following conditions: 1. Acute ST-segment elevation myocardial infarction (STEMI); 2. Non-ST-segment elevation ACS (NSTE-ACS); 3. ACS patients undergoing coronary artery bypass grafting (CABG); 4. Patients with unstable angina pectoris.

Exclusion criteria

Exclusion criteria: 1.Severe hepatic insufficiency; 2.Pregnant or lactation women; 3.The researchers concluded that there are other factors that are not suitable for participating in the study.

Design outcomes

Primary

MeasureTime frame
plasma concentration;Gene detection;Dyspnea grade;—

Secondary

MeasureTime frame
Major Adverse Cardiovascular Events;Blood uric acid level;—

Countries

China

Contacts

Public ContactAilan Chen

The First Affiliated Hospital of Guangzhou Medical University

1228327958@qq.com+86 13719198832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026